


PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁷ : C07D 307/33, C07J 31/00, C07H 71/00</p>	<p>A2</p>	<p>(11) International Publication Number: WO 00/64882 (43) International Publication Date: 2 November 2000 (02.11.00)</p>
<p>(21) International Application Number: PCT/EP00/02705 (22) International Filing Date: 28 March 2000 (28.03.00) (30) Priority Data: 9909229.8 23 April 1999 (23.04.99) GB (71) Applicant (for all designated States except US): GLAXO GROUP LIMITED [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): ANDERSEN, Marc, Werner [US/US]; 4108 Balsam Drive, Raleigh, NC 27612 (US). BOSWELL, Grady, Evan [US/US]; 1661 Scuffle Town Road, Fountain Inn, SC 29644 (US). SHARP, Matthew, Jude [GB/US]; Glaxo Wellcome Inc., Five Moore Drive, Research Triangle Park, NC 27709 (US). ZHOU, Xiaoming [CN/US]; Glaxo Wellcome Inc, Five Moore Drive, Research Triangle Park, NC 27709 (US). (74) Agent: TEUTEN, Andrew, J.; Glaxo Wellcome plc, Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).</p>		<p>(81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published Without international search report and to be republished upon receipt of that report.</p>
<p>(54) Title: ENANTIOMERS OF MERCAPTO LACTONES AND PROCESSES FOR THEIR SYNTHESIS</p> <div style="text-align: center;">  <p>(I)</p> </div> <p>(57) Abstract</p> <p>An improved process for the preparation of single enantiomers of formula (I), and novel intermediates and processes thereto.</p>		

FOR THE PURPOSES OF INFORMATION ONLY


Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		


Enantiomers of Mercapto Lactones and Processes for their Synthesis

The present invention relates to a new process for the synthesis of enantiomers of mercapto lactones, and their acyl derivatives which are useful intermediates in the preparation of compounds of formula (I).


Compounds of formula (I) have the following structure



in which R¹ individually represents OC(=O)C₁₋₆alkyl; R² individually represents hydrogen, methyl (which may be in either the α or β configuration) or methylene; or R¹ and R² together represent




wherein R³ and R⁴ are the same or different and each represents hydrogen or C₁₋₆ alkyl; X¹ and X² are the same or different and each represents hydrogen or halogen; --- represents a single or double bond; and n=0 or 1. These compounds were first described in PCT patent publications WO97/24365 and WO97/24367. Currently there is considerable interest in compounds of formula (I), for example compound A, as anti-inflammatory and anti-allergic compounds in the treatment of asthma and other inflammatory diseases.



Compound A is 16 α , 17 α -(R-butyridenedioxy)-6 α ,9 α -difluoro-11 β -hydroxy-3-oxo-androst-4-ene-17 β -carbothioic acid S-(2-oxo-tetrahydro-furan-3S-yl) ester.


- 5 The route of synthesis of the compound A described in the specification of WO97/24365 is specifically described therein in example 19.

One route to compounds of general formula (I), in which $n = 0$, described in WO97/24365 involves coupling a carboxylic acid of formula (II)



10

with racemic α -mercapto- γ -butyrolactone (formula (III))




to yield a 1:1 mixture of lactone diastereoisomers of formula (I) which require separation.


15

Due to the separation step this method is not amenable to large scale synthesis.

A further route referred to in WO97/24365 for when $n=0$ involves the conversion of a compound of formula (II) to a compound of formula (IV), using difficult and toxic reagents such as hydrogen sulphide gas.




- 5 The compound of formula (IV) is then reacted with an enantiomerically pure compound of formula (V)



in which X represents a suitable leaving group, (for example chloro, bromo, or OSO_2A wherein A is CH_3 , CF_3 , or $p\text{-CH}_3\text{C}_6\text{H}_4$) to yield a single diastereoisomer of formula (I).


- 10 This process requires the use of hydrogen sulphide gas, which is very toxic and difficult to handle. Furthermore, the compound of formula (IV) is not stable on storage and must be kept cold. Also, the route is long since it requires an additional synthetic transformation.

- 15 One route to compounds of general formula (I), in which $n = 1$, described in WO97/24365, involves treating a compound of formula (VI)



wherein R^1 , R^2 , X^1 and X^2 are as previously defined, and L represents a suitable leaving group such as a sulphonate ester, for example a mesylate, tosylate or triflate, or L represents a halogen such as chloro or bromo,

5 with racemic α -mercapto- γ -butyrolactone (formula (III))





10 to yield a 1:1 mixture of lactone diastereoisomers of formula (I) wherein $n = 1$ which require separation. Due to the separation step this method is not amenable to large scale synthesis.


15 An ideal route for the synthesis of a compound of formula (I) should produce the compound in high yields at a reasonable speed and at low cost with minimum waste materials and in a manner that is of minimum impact to the environment in terms of energy consumption and disposal of waste-materials.

20 We have found a new process for the synthesis of the enantiomers of compounds of formula (III), providing many advantages in the preparation of compounds of formula (I) over previously known routes of synthesis. Such advantages include avoiding the need for a difficult separation step, avoiding the use of unpleasant and toxic reagents such as hydrogen sulphide gas, lower cost, less waste, and more efficient use of materials.

The single enantiomers of compound (III), (S)- α -mercapto- γ -butyrolactone and (R)- α -mercapto- γ -butyrolactone, are represented by the formulae (IIIa) and (IIIb).



The single enantiomer of formula (IIIa), substantially free of the corresponding enantiomer, may be prepared by the following reaction sequence, which is presented as a feature of the present invention:



In formula (VIIIa), A represents CH_3 , CF_3 , or $\text{p-CH}_3\text{C}_6\text{H}_4$, more preferably CH_3 . In formula (IXa), R represents C_{1-6} alkyl or phenyl optionally substituted by one or more substituents selected from halo, C_{1-3} alkyl, hydroxy, and C_{1-3} alkoxy, more preferably R is CH_3 .

10

Step A is carried out by treating a compound of formula (VIIa) with a sulfonyl chloride or sulfonic anhydride, preferably methanesulfonyl chloride or trifluoromethanesulfonyl chloride (most preferably methanesulfonyl chloride) preferably in the presence of a base, for example a trialkylamine base such as triethylamine or diisopropylethylamine, or an aromatic base such as pyridine, lutidine or 4-N,N-dimethylaminopyridine (most preferably the base will be triethylamine or 4-N,N-dimethylaminopyridine, especially triethylamine and 4-N,N-dimethylaminopyridine), and preferably in a suitable solvent, for example aromatic solvents such as toluene, ester solvents such as ethyl acetate, ether solvents such as tetrahydrofuran (THF), dimethoxyethane and dioxane, amides such as dimethylformamide, ketones such as methyl isobutyl ketone, or chlorinated hydrocarbons such as dichloromethane. Preferably the solvent is selected from the group consisting of dichloromethane, ethyl acetate and methyl isobutyl ketone; most preferably the solvent is ethyl acetate. Preferably, the reaction is carried out at a temperature in the range of -40°C to ambient temperature, most preferably from 10°C to 20°C . Step A will then be completed by recrystallisation of the compound of formula (VIIIa) according to appropriate conditions, preferably using ethyl acetate for recrystallisation.

25

Step B is carried out by treating a compound of formula (VIIIa) with a thiocarboxylate salt (especially a thioacetate salt). Suitable thiocarboxylate salts include inorganic salts (such as potassium or cesium), trialkylamine salts (such as triethylamine), or aromatic

30


amine salts (such as pyridine and lutidine). The thiocarboxylate salts are either commercially available, prepared by standard methods, or generated in situ from thiocarboxylic acid; the preferred thiocarboxylate salt is potassium thioacetate.

Preferably, the reaction is carried out in a suitable solvent, for example aromatic

solvents such as toluene, esters such as ethyl acetate, amides such as dimethylformamide, ethers such as THF, dioxane, and dimethoxyethane, or chlorinated hydrocarbons such as dichloromethane. Preferably the solvent is selected from the group consisting of toluene, dimethoxyethane and THF; more preferably, the solvent is toluene. Preferably, the reaction is carried out at a temperature in the range of -20°C to ambient temperature, most preferably room temperature (20°C).

Step C is carried out by reacting a compound of formula (IXa) with an aliphatic alcohol, for example methanol or ethanol, preferably methanol, in the presence of an inorganic acid, for example hydrochloric acid, or alternatively with an aromatic amine, for example 4-chloroaniline; preferably the aliphatic alcohol will be present with hydrochloric acid. Preferably the reaction is carried out in the presence of a suitable solvent, for example aromatic solvents such as toluene, ether solvents such as dioxane or THF, or chlorinated solvents such as dichloromethane. Preferably, the solvent is toluene or dioxane; more preferably, the solvent is toluene. Step C will then be completed by vacuum distillation of the compound of formula (IIIa) according to appropriate conditions.

The single enantiomer of formula (IIIb), substantially free of the corresponding enantiomer, may be prepared by an analogous process in which reagents and conditions are as in steps A, B and C above, and which is presented as a further feature of the present invention, using as starting material the (S) enantiomer (VIIb) as follows



Substituents A and R in formulae (VIIIb) and (IXb) respectively are as defined above for formulae (VIIIa) and (IXa).


Enantiomeric compounds (IIIa), (IIIb), (IXa) and (IXb), substantially free of the corresponding enantiomer, are novel and are presented as further features of the present invention.

5

By 'substantially free' is meant no more than about 10% w/w of the corresponding enantiomer, particularly no more than about 5% w/w, and more particularly less than about 3% w/w is present.

10 Compounds (IXa) and (IXb) wherein R is methyl, are (S)- α -acetylthio- γ -butyrolactone and (R)- α -acetylthio- γ -butyrolactone respectively.

Alternatively, the single enantiomers (IXa) and (IIIb) may be prepared by an enzymatic transacetylation reaction of racemic compound (IX), which is presented as a further
15 feature of the present invention. Compound (IXa) prepared in this manner may then be separated from compound (IIIb) by distillation and converted to compound (IIIa) as illustrated in the reaction scheme above.




This transacetylation reaction is preferably carried out in the presence of an alcohol,
20 such as butanol, benzyl alcohol, hexanol or octanol, most preferably butanol, and a suitable lipase or esterase enzyme, preferably *mucor meihei* lipase, in toluene and/or isooctane, most preferably toluene, containing a small amount of water. Preferably, the reaction will be carried out at a temperature in the range of -20°C to room temperature, most preferably 5°C.

25

The compounds (VIIa) and (VIIb) are commercially available. Racemic compound (IX) may be prepared by the method described in Fuchs, Swed. Ark. Kemi (1966), 26 (10), 111-116. Compounds of formula (II) may be prepared by methods known in the art, for example by the methodology described in Kertesz and Marx, Journal of Organic

Chemistry, 1986, 51, 2315-2328, the contents of which are incorporated herein by reference hereto.

Compounds (IIIa) and (IIIb) may be used directly in the preparation of single diastereoisomers of compounds of formula (I) in which $n=0$ by reaction with a compound of formula (II):



This represents a cost effective, convergent synthesis of a single diastereoisomer of formula (I) in high yield with no separation step.

10

This reaction is presented as a further feature of the present invention. Preferably, the reaction is carried out in a solvent, for example amide solvents such as N,N-dimethylformamide and N-methyl-2-pyrrolidinone; ester solvents such as ethyl acetate and isopropyl acetate; ketone solvents such as acetone, 2-butanone and 4-methyl-2-pentanone; hydrocarbon solvents such as toluene; halogenated solvents such as dichloromethane; and nitrile solvents such as acetonitrile. Preferably, the solvent is acetone.


15

The reaction is carried out in the presence of a base. Preferably the base is a weak inorganic base such as sodium acetate or sodium bicarbonate. Potassium carbonate is an alternative base, but sodium bicarbonate is especially preferred.

20

The reaction is carried out in the presence of a coupling agent. Preferably, the coupling agent is *O*-benzotriazole-1-yl-*N,N,N',N'*-tetramethyluronium hexafluorophosphate (or its corresponding tetrafluoroborate salt). Preferably, the coupling agent is added to the compound of formula (II) at a temperature in the range 0 to 100 °C. Preferably, the coupling step with the compound of formula (III) is carried out at a temperature in the range -10 °C to ambient temperature, most preferably 4°C. This reaction will then be completed by recrystallisation of the compound of formula (I) according to appropriate conditions, preferably using isopropyl acetate and heptane for recrystallisation.


- 10 Compounds of formula (II) may alternatively be prepared according to the following process:



- Step A is carried out in the presence of hydrogen peroxide and a base. Preferably the base is a weak inorganic base such as potassium carbonate, preferably the reaction will be carried out in the presence of an aliphatic alcohol, most preferably methanol, preferably at room temperature. Step A will then be completed by recrystallisation of the compound of formula (II) according to appropriate conditions, preferably using ethyl acetate for recrystallisation.

- 20 Compounds (IIIa) and (IIIb) may also be used directly in the preparation of single diastereoisomers of compounds of formula (I) in which n=1 by reaction with a compound of formula (VI):

10



This represents a cost effective, convergent synthesis of a single diastereoisomer of formula (I) where $n = 1$ in high yield with no separation step. The reaction conditions are as described above for the reaction of compounds of formulae (II) and (IIIa) or (IIIb).

5

The invention is further described by following examples, which are presented by way of illustration only.

In the Examples, unless otherwise stated:

10

All temperatures refer to °C. Proton Magnetic Resonance ($^1\text{H-NMR}$) spectra were recorded at 300 MHz, chemical shifts are reported in ppm (δ) from Me_4Si , used as internal standard, and are assigned as singlets (s), doublets (d), doublet of doublets (dd), triplets (t), doublet of triplets (dt), quartets (q) or multiplets (m). The following abbreviations are used in text: AcOEt = ethyl acetate, TFA = trifluoroacetic acid, HCl = hydrochloric acid, EtOH = ethanol.

15

20

Example 1**(S)- α -mercapto- γ -butyrolactone****A. (R)- α -(Methylsulfonyl)oxy- γ -butyrolactone**

5 Triethylamine (45ml, 323mmol) and 4-N,N-dimethylaminopyridine (3.6g, 29mmol) in anhydrous AcOEt (75ml) were added to a stirred solution of (R)-(+)- α -hydroxy- γ -butyrolactone (30g, 294mmol) in anhydrous AcOEt (300ml), under N₂, at -40°. The solution was stirred for 10min. Methanesulfonyl chloride (25ml, 323mmol) was added slowly to the reaction, maintaining the temperature below -35°. The mixture was stirred
10 for 2h at -40°. Upon completion the mixture was allowed to warm up to ambient temperature. The mixture was diluted with AcOEt (450ml) and filtered. The solid was washed with AcOEt (3x60ml). The filtrate was washed with a solution of 50% H₂O and 50% brine (60ml). The organic layer was washed with 1N HCl (45ml), a solution of 50% H₂O and 50% saturated brine (45ml), a saturated aqueous NaHCO₃ solution (45ml), and
15 a solution of 50% H₂O and 50% brine (2x45ml). The solvent (780ml) was removed under reduced pressure and hexanes (500 ml) was added to the mixture. The mixture was stirred at 5° for 2h. The mixture was filtered, and solid was dried under vacuum at room temperature to yield (R)- α -(methylsulfonyl)oxy- γ -butyrolactone as a white solid (45g, 85%). ¹H-NMR (CDCl₃): δ 5.32 (1H, t, J=8.7Hz), 4.52 (1H, m), 4.33 (1H, m), 3.27
20 (3H, s), 2.76 (1H, m), 2.56 (1H, m).

B. (S)- α -acetylthio- γ -butyrolactone

Potassium thioacetate (7.33g, 64.17mmol) was added to a solution of (R)- α -(methylsulfonyl)oxy- γ -butyrolactone (11g, 61.11mmol) in toluene (220ml) at 5°. The
25 reaction mixture was stirred at ambient temperature for 36 h. The mixture was filtered and the solid was washed with toluene (3x22ml). The organic layer was washed with water (3 ml) and 1N HCl (3 ml). The organic solution was dried over sodium sulfate, the toluene was removed by rotary evaporation to give (S)- α -acetylthio- γ -butyrolactone as a liquid (9.2g, 94% yield): 98% e.e. (HPLC, column: Daicel AD, 10% EtOH / Hexanes, flow
30 1ml/min); ¹H-NMR (CDCl₃): δ 4.40 (1H, m), 4.26 (1H, m), 4.23 (1H, m), 2.70 (1H, m), 2.35 (3H, s), 2.23 (1H, m). ¹³C-NMR (75MHz, CDCl₃): δ 193.59, 174.72, 66.95, 40.46,

30.42, 30.30. Anal. Calcd for $C_6H_8O_3S$: C, 44.99; H, 5.03; S, 20.02. Found: C, 44.81; H, 5.05; S, 20.10%.

C. (S)- α -mercapto- γ -butyrolactone

- 5 Methanol (46ml) and 4M HCl in dioxane (9.2ml, 36.8mmol) were added to (S)- α -acetylthio- γ -butyrolactone (9.2g, 58mmol) in toluene (138ml) at 0°. The solution was stirred at ambient temperature overnight. Upon completion of the reaction, 92ml of solvents were removed under vacuum. Toluene (92ml) and TFA (0.1 ml) was added to give a pH of 1.5-2.0. The solution was stirred overnight. Toluene was removed under vacuum to give crude product. The crude product was dried under vacuum for 15min at ambient temperature. Vacuum distillation gave (S)- α -mercapto- γ -butyrolactone (5.9g, 87% yield) (b.p. 50-51°, 200millitorr): 98% e.e. (HPLC, column: Daicel AD, 10% EtOH/Hexanes, flow 1ml/min). 1H -NMR ($CDCl_3$): δ 4.47 (1H, m), 4.32 (1H, m), 3.72 (1H, m), 2.69 (1H, m), 2.33 (1H, d, J=4.8Hz), 2.18 (1H, m). ^{13}C -NMR (75MHz, $CDCl_3$): δ 176.89, 66.77, 34.97, 32.09. Anal. Calcd for $C_4H_6O_2S$: C, 40.66; H, 5.12; S, 27.14. Found: C, 40.61; H, 5.13; S, 26.99%.
- 10
- 15

Example 2

- 20 16 α ,17 α -(R-butylienedioxy)-6 α ,9 α -difluoro-11 β -hydroxy-3-oxo-androst-4-ene-17 β -carbothioic acid S-(2-oxo-tetrahydro-furan-3S-yl) ester.

Step A)

- 25 6 α , 9 α , Difluoro-11 β -hydroxy-16 α , 17 α -isopropylidenedioxy-3-oxo-androst-4-ene-17 β carboxylic acid
- A mixture of 1,2-dihydrofluocinolone acetonide (5.0g, 11.0 mmol), potassium carbonate (4.56g, 33.0 mmol) and hydrogen peroxide (18.5 ml, 16.5 mmol as a 3% wt/vol. solution in water) was stirred in methanol (35 ml) at ambient temperature for 24 hours. The mixture was then treated with additional hydrogen peroxide (12 ml, 11.0 mmol) for an additional 24-hour period. Water (25 ml) was added and the solution was washed with ethyl acetate (25 ml) followed by hexanes (25 ml). The aqueous layer was then adjusted to pH 2 by addition of concentrated HCl, which resulted in a precipitate. The acidic aqueous layer was washed with ethyl acetate (2x25 ml) and the combined ethyl acetate extracts evaporated to dryness. The resulting off white solid was triturated in 1:1.
- 30

hexanes-ethyl acetate (30ml) and filtered and dried at 50°C for 24 hours to provide the title compound as a off-white solid. (3.93g, 81%). ¹H-NMR (DMSO-d₆): 5.77(s, 1H), 5.55 and 5.40(2m, 1H), 5.1(m, 1H), 4.90(m, 1H), 4.10(m, 1H), 2.5-2.35(m, 3H), 2.35-2.1(2m, 3H), 2.0-1.85(m, 3H), 1.7-1.4 (m, overlapping s at 1.45, 5H) 1.35-1.20(m overlapping s at 1.29, 4H), 1.13 (s, 3H), 0.9 to 0.75 (m, overlapping s at 0.87, 4H).

Step B)

16 α , 17 α -(R-butylienedioxy)-6 α , 9 α -difluoro-11 β -hydroxy-3-oxo-androst-4-ene-17 β -carboxylic acid

70% perchloric acid (22.8ml, 264mmol) was added to a stirred mixture butyraldehyde (11ml, 122mmol) and 6 α , 9 α -difluoro-11 β -hydroxy-16 α , 17 α -isopropylidenedioxy-3-oxo-androst-4-ene-17 β carboxylic acid (30.40g, 69mmol) in dichloromethane (608ml) at -3 °C. The mixture was stirred overnight at -3 °C and then 6% aqueous sodium carbonate (248ml) was added. The mixture was then allowed to warm to room temperature and 6% aqueous sodium carbonate (304ml) was added. After 3 hours the phases were separated and the organic phase was extracted with 6% aqueous sodium carbonate (2x60ml). The combined aqueous phase was washed with toluene (2x150ml). Then, the aqueous phase was rapidly stirred as conc. hydrochloric acid was added until a pH of 2-1 was obtained. The resulting slurry was suction-filtered, and the filter plug was washed with water (3x60ml) and dried in air overnight to give a crude product (31g, containing 9% of the undesired acetal epimer). The crude product was dissolved in EtOH-water (1:2, ca. 532ml) by heating at 72-73 °C and the resulting solution was allowed to cool to room temperature overnight. The mixture was filtered, and the solid was washed with 30ml of water. The solid was dried in a vacuum oven at 90-100 °C to give the product (24g) with 1.6% of epimer. Recrystallization was repeated (12vol EtOH-water 1:2, ca. 430 ml). The product was dried in a vacuum oven at 90-100 °C to provide the title compound as an off-white solid (21.6g, 69% total yield, containing 0.3-0.5 % of the undesired epimer). ¹H-NMR (300 MHz, DMSO, d₆) δ 0.86 (t, 3H); 0.92 (s, 3H); 1.31-1.57 (m, 7H); 1.47 (s, 3H); 1.74 (d, 1H); 1.91-2.42 (m, 8H); 4.14 (m, 1H); 4.62 (t, 1H); 4.87 (br, 1H); 5.14 (br, 1H); 5.42-5.57(m, 1H); 5.81(s, 1H).

Step C)

16 α ,17 α -(R-butylienedioxy)-6 α ,9 α -difluoro-11 β -hydroxy-3-oxo-androst-4-ene-17 β -carbothioic acid S-(2-oxo-tetrahydro-furan-3S-yl) ester.

A mixture of 16 α ,17 α -(R-butylienedioxy)-6 α ,9 α -difluoro-11 β -hydroxy-3-oxo-androst-4-ene-17 β -carboxylic acid (6.00g, 13.2mmol), O-benzotriazole-1-yl-N,N',N'-tetramethyluronium hexafluorophosphate (HBTU, 5.98g, 15.8mmol), and sodium bicarbonate (2.28g, 27mmol), in acetone (45ml) was stirred under nitrogen and heated at 43° for 16h. The mixture was cooled to 0° and treated with more sodium bicarbonate (2.28g, 27mmol) then a solution of (S)- α -mercapto- γ -butyrolactone (ca. 98% e.e., 2.34g, 19.80mmol) in acetone (3ml). The mixture was stirred at 0° for 25h and the cold reaction mixture was then poured into isopropyl acetate (100ml). 1 N HCl (50 ml) was then added and the layers were separated. The organic layer was washed with 5% potassium carbonate (50 ml) then brine (50 ml) and dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was then crystallized from hot isopropylacetate (24ml). The resulting slurry was suction-filtered and the white solid dried in a vacuum oven at 80° for 3 days affording the title compound (5.45g, 75% yield). M.pt. 169-173°; ¹H-NMR (CDCl₃) δ 6.13 (1H,s); 5.26 (1H, dm, J = 47.5 Hz); 4.84 (1H, d, J = 5.2 Hz); 4.73 (1H, t, J = 4.2Hz); 4.47 (1H, dt, J = 8.6 Hz, 2.9 Hz); 4.4 - 4.28 (3H,m); 2.75 (1H,m); 2.6 - 2.4 (3H,m); 2.4 - 2.18 (4H,m); 2.0 (1H,m); 1.9 - 1.6 (8H,m); 1.52 (3H,s); 1.46 (2H, q, J = 7 Hz); 1.00 (3H,s); 0.95 (3H, t, J = 7.3 Hz).

The compound of Example 2 is capable of preparation according to the invention at an overall yield of 30% in 4 linear steps from the starting material (fluocinoline acetonide), resulting in a product with <2% of the undesired lactone isomer. This is clearly advantageous when compared with previously known syntheses, the best of which obtain the compound in 5 linear steps from identical starting material, obtaining an overall yield of 8% and resulting in a much less pure end product (approximately 5% of the undesired lactone isomer).

CLAIMS

1. (S)- α -acetylthio- γ -butyrolactone substantially free of the corresponding enantiomer.


5 2. (R)- α -acetylthio- γ -butyrolactone substantially free of the corresponding enantiomer.

3. (S)- α -mercapto- γ -butyrolactone substantially free of the corresponding enantiomer.

10

4. (R)- α -mercapto- γ -butyrolactone substantially free of the corresponding enantiomer.


5. A process for the preparation of a compound of formula (IXa)



15

wherein R represents C₁₋₆ alkyl or phenyl optionally substituted by one or more substituents selected from halo, C₁₋₃ alkyl, hydroxy, and C₁₋₃ alkoxy; comprising


a) treating a compound of formula (VIIa)



20


with a sulfonyl chloride or sulfonic anhydride in the presence of a base; and

b) treating the resultant compound of formula (VIIIa)




wherein A represents CH_3 , CF_3 , or $p\text{-CH}_3\text{C}_6\text{H}_4$; with a thiocarboxylate salt.

6. A process for the preparation of a compound of formula (IXb)




5 wherein R represents C_{1-6} alkyl or phenyl optionally substituted by one or more substituents selected from halo, C_{1-3} alkyl, hydroxy, and C_{1-3} alkoxy; comprising

a) treating a compound of formula (VIIb)




with a sulfonyl chloride or sulfonic anhydride in the presence of a base; and

10 b) treating the resultant compound of formula (VIIIb)




wherein A represents CH_3 , CF_3 , or $p\text{-CH}_3\text{C}_6\text{H}_4$; with a thiocarboxylate salt.

7. A process for the preparation of a compound of formula (IIIa)



15


comprising reacting a compound of formula (IXa)




wherein R represents C₁₋₆ alkyl or phenyl optionally substituted by one or more substituents selected from halo, C₁₋₃ alkyl, hydroxy, and C₁₋₃ alkoxy; with an aliphatic alcohol in the presence of an inorganic acid, or alternatively with an aromatic amine.

5

8. A process for the preparation of a compound of formula (IIIb)




comprising reacting a compound of formula (IXb)




- 10 wherein R represents C₁₋₆ alkyl or phenyl optionally substituted by one or more substituents selected from halo, C₁₋₃ alkyl, hydroxy, and C₁₋₃ alkoxy; with an aliphatic alcohol in the presence of an inorganic acid, or alternatively with an aromatic amine.

9. A process for the preparation of compounds of formulae (IXa) and (IIIb)




15

wherein R represents C₁₋₆ alkyl or phenyl optionally substituted by one or more substituents selected from halo, C₁₋₃ alkyl, hydroxy, and C₁₋₃ alkoxy; comprising the enzymatic transacetylation of racemic compound (IX)




wherein R is as defined above, in the presence of an alcohol and a suitable lipase or esterase enzyme in a solvent containing water.

- 5 10. A process for the preparation of a single enantiomer of a compound of formula (I)





in which R¹ individually represents OC(=O)C₁₋₆alkyl; R² individually represents hydrogen, methyl (which may be in either the α or β configuration) or methylene; or R¹ and R² together represent




wherein R³ and R⁴ are the same or different and each represents hydrogen or C₁₋₈ alkyl; X¹ and X² are the same or different and each represents hydrogen or halogen;

--- represents a single or double bond; and n=0; comprising the reaction of a compound of formula (IIIa) or (IIIb)




with a compound of formula (II)




in which R^1 , R^2 , X^1 and X^2 are as defined above for formula (I), in the presence of a base and a coupling agent.

- 5 11. A process according to claim 10 wherein the base is sodium bicarbonate and the coupling agent is *O*-benzotriazole-1-yl-*N,N,N',N'*-tetramethyluronium hexafluorophosphate.

- 10 12. A process for the preparation of a single enantiomer of a compound of formula (I)




- 15 in which R^1 individually represents $OC(=O)C_{1-6}alkyl$; R^2 individually represents hydrogen, methyl (which may be in either the α or β configuration) or methylene; or R^1 and R^2 together represent




wherein R^3 and R^4 are the same or different and each represents hydrogen or C_{1-6} alkyl;
 X^1 and X^2 are the same or different and each represents hydrogen or halogen;

--- represents a single or double bond; and $n=1$; comprising the reaction of a
 5 compound of formula (IIIa) or (IIIb)



10 with a compound of formula (VI)



in which R^1 , R^2 , X^1 and X^2 are as defined above for formula (I), and L represents a
 suitable leaving group, in the presence of a base and a coupling agent.

15 13. A process according to claim 12 wherein the base is sodium bicarbonate and
 the coupling agent is O-benzotriazole-1-yl- N,N,N',N' -tetramethyluronium
 hexafluorophosphate.

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
2 November 2000 (02.11.2000)

PCT

(10) International Publication Number
WO 00/64882 A3

(51) International Patent Classification⁷: C07D 307/33, C07J 31/00, 71/00

(74) Agent: TEUTEN, Andrew, J.; Glaxo Wellcome plc, Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).

(21) International Application Number: PCT/EP00/02705

(22) International Filing Date: 28 March 2000 (28.03.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
9909229.8 23 April 1999 (23.04.1999) GB

(71) Applicant (for all designated States except US): **GLAXO GROUP LIMITED** [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ANDERSEN, Marc, Werner** [US/US]; 4108 Balsam Drive, Raleigh, NC 27612 (US). **BOSWELL, Grady, Evan** [US/US]; 1661 Scuffle Town Road, Fountain Inn, SC 29644 (US). **SHARP, Matthew, Jude** [GB/US]; Glaxo Wellcome Inc., Five Moore Drive, Research Triangle Park, NC 27709 (US). **ZHOU, Xiaoming** [CN/US]; Glaxo Wellcome Inc., Five Moore Drive, Research Triangle Park, NC 27709 (US).


Published:

— With international search report.

(88) Date of publication of the international search report:
22 February 2001

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ENANTIOMERS OF MERCAPTO LACTONES AND PROCESSES FOR THEIR SYNTHESIS



(57) Abstract: An improved process for the preparation of single enantiomers of formula (I), and novel intermediates and processes thereto.

WO 00/64882 A3

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 00/02705

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D307/33 C07J31/00 C07J71/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D C07J

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data, EPO-Internal, WPI Data, BEILSTEIN Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 97 24365 A (GLAXO GROUP LIMITED, UK; BIGGADIKE, KEITH; PROCOPIOU, PANAYIOTIS ALEXAN) 10 July 1997 (1997-07-10) cited in the application abstract; claims 1,3 page 20 -page 44; examples page 14, line 10 -page 16, line 3 --- -/--	1-13

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

13 November 2000

Date of mailing of the international search report

30/11/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl
Fax: (+31-70) 340-3016

Authorized officer

Paisdor, B

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 00/02705

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	CHEMICAL ABSTRACTS, vol. 66, no. 7, 13 February 1967 (1967-02-13) Columbus, Ohio, US; abstract no. 28363, FUCHS, GEORG: "Some 2- or 3-mercapto substituted.gamma.-lactones" XP002152698 cited in the application abstract & ARK. KEMI (1966), 26(10), 111-16 ,	1-13
A	----- ZHENG T -C ET AL: "A General and Mild Synthesis of Thioesters and Thiols from Halides" TETRAHEDRON LETTERS,NL,ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, vol. 40, no. 4, 22 January 1999 (1999-01-22), pages 603-606, XP004151396 ISSN: 0040-4039 page 605; table II	1-5
A	----- SH.-JAN SHIUEY ET AL.: "Triply Convergent Synthesis of 1alpha,25-Dihydroxy-24(R)-fluorocholecalci ferol" JOURNAL OF ORGANIC CHEMISTRY, vol. 53, 1988, pages 1040-1046, XP002152696 EASTON US page 1041; figures II,III	1-4
A	----- F. MATSUDA ET AL.: "A Formal Synthesis of Aplasmomycin" CHEMISTRY LETTERS, 1987, pages 2097-2100, XP002152697 TOKYO JP page 2098; example 5 -----	1-4

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 00/02705

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9724365 A	10-07-1997	AT 194356 T	15-07-2000
		AU 721865 B	13-07-2000
		AU 1140997 A	28-07-1997
		BG 102625 A	30-04-1999
		BR 9612309 A	13-07-1999
		CA 2241728 A	10-07-1997
		CN 1209135 A	24-02-1999
		CZ 9802074 A	11-11-1998
		DE 69609199 D	10-08-2000
		EP 0876392 A	11-11-1998
		HU 9903707 A	28-03-2000
		JP 2947944 B	13-09-1999
		JP 11501675 T	09-02-1999
		NO 983004 A	26-08-1998
		NZ 324373 A	28-10-1999
		PL 327629 A	21-12-1998
		SK 89198 A	10-03-1999